Komori
Share Issuance and Disposal4563AnGes,Inc.Pharmaceuticals

(Correction) Acquisition and cancellation of Stock Acquisition Rights (46), redemption of the Second Series Bonds and revision of the exercise price of Stock Acquisition Rights (47) and (48), issuance of the Second Series Bonds with Stock Acquisition Rights, and a business partnership agreement with GP社

Regarding the disclosure published on 14 August 2026 concerning the issuance of stock acquisition rights and bonds, the headings explaining the changes and the timing of execution of the agreement were corrected, and the amounts of estimated issuance expenses and estimated net proceeds were revised.

Worth reading
26Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
570
yen
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure14 August 2026

Notice concerning the acquisition and cancellation of Series 46 Stock Acquisition Rights (with exercise price adjustment provisions), termination of the unsecured privately placed bond facility agreement (revolving type), redemption of Series 2 Unsecured Bonds (privately placed bonds), issuance by third-party allotment of Series 47 Stock Acquisition Rights (with exercise price adjustment provisions), Series 48 Stock Acquisition Rights and Series 2 Unsecured Convertible Bonds with Stock Acquisition Rights, and execution of a business alliance agreement with グロースパートナーズ株式会社

Open the original document
11 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-08-25
Location of correction (where in the original document)

II. Termination of the Bond Facility Agreement and Redemption of Series 2 Unsecured Bonds (Privately Placed Bonds), 1. heading; III. Overview of the Third-Party Allotment, 1. (1) Overview of the Offering of Series 47 Stock Acquisition Rights, item ⑨; 3. Amount of Funds to Be Raised, Use of Funds and Scheduled Timing of Expenditures, (1) Amount of Funds to Be Raised; 5. Reasonableness of the Issuance Terms, etc., (1) Basis for Calculating the Issue Price and Specific Details, ③ These Convertible Bonds with Stock Acquisition Rights; and 9. Matters Relating to Procedures under the Corporate Code of Conduct

Before correction

Estimated issuance expenses: ¥303,870,570; estimated net proceeds: ¥8,196,131,745

After correction

Estimated issuance expenses: ¥303,870,000; estimated net proceeds: ¥8,196,132,315

ChangesEstimated issuance expenses decreased by ¥570, while estimated net proceeds increased by ¥570.
Reason for correction

Because some errors were found in the disclosure published on 14 August 2026.

What was corrected and how
ItemDetails
Disclosure subject to correctionNotice concerning the acquisition and cancellation of Series 46 Stock Acquisition Rights (with exercise price adjustment provisions), termination of the unsecured privately placed bond facility agreement (revolving type), redemption of Series 2 Unsecured Bonds (privately placed bonds), issuance by third-party allotment of Series 47 Stock Acquisition Rights (with exercise price adjustment provisions), Series 48 Stock Acquisition Rights and Series 2 Unsecured Convertible Bonds with Stock Acquisition Rights, and execution of a business alliance agreement with グロースパートナーズ株式会社
Original disclosure date14 August 2026
Location of correctionII. Termination of the Bond Facility Agreement and Redemption of Series 2 Unsecured Bonds (Privately Placed Bonds), 1. heading; III. Overview of the Third-Party Allotment, 1. (1) Overview of the Offering of Series 47 Stock Acquisition Rights, item ⑨; 3. Amount of Funds to Be Raised, Use of Funds and Scheduled Timing of Expenditures, (1) Amount of Funds to Be Raised; 5. Reasonableness of the Issuance Terms, etc., (1) Basis for Calculating the Issue Price and Specific Details, ③ These Convertible Bonds with Stock Acquisition Rights; and 9. Matters Relating to Procedures under the Corporate Code of Conduct
Details of correctionEstimated issuance expenses: ¥303,870,570; estimated net proceeds: ¥8,196,131,745 → Estimated issuance expenses: ¥303,870,000; estimated net proceeds: ¥8,196,132,315
Reason for correctionBecause some errors were found in the disclosure published on 14 August 2026.
Items this document does not state (1)
Impact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because some errors were found in the disclosure published on 14 August 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Acquisition and cancellation of Stock Acquisition Rights (46), redemption of the Second Series Bonds and revision of the exercise price of Stock Acquisition Rights (47) and (48), issuance of the Second Series Bonds with Stock Acquisition Rights, and a business partnership agreement with GP社 | AnGes,Inc. (4563) timely disclosure | Komori